Matches in Nanopublications for { ?s ?p "[NZ-1 neutralizes the interaction between podoplanin and CLEC-2, which may lead to the development of therapeutic antibodies against podoplanin-dependent cancer metastasis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- NP102806.RAU8e0FZgexZM5cUgx13gKpB1Orf4DZM0ugAWIA0szntQ130_assertion description "[NZ-1 neutralizes the interaction between podoplanin and CLEC-2, which may lead to the development of therapeutic antibodies against podoplanin-dependent cancer metastasis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP102806.RAU8e0FZgexZM5cUgx13gKpB1Orf4DZM0ugAWIA0szntQ130_provenance.
- NP102995.RAaCSmNJP1FxeVfizjY3p7xw_8IPaSCgSjTsthY6h_hvk130_assertion description "[NZ-1 neutralizes the interaction between podoplanin and CLEC-2, which may lead to the development of therapeutic antibodies against podoplanin-dependent cancer metastasis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP102995.RAaCSmNJP1FxeVfizjY3p7xw_8IPaSCgSjTsthY6h_hvk130_provenance.
- NP112622.RA4VBXkCxHAQzQ3cKgu70wz2bFDe4hDG0AK6vRpeRqDPw130_assertion description "[NZ-1 neutralizes the interaction between podoplanin and CLEC-2, which may lead to the development of therapeutic antibodies against podoplanin-dependent cancer metastasis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP112622.RA4VBXkCxHAQzQ3cKgu70wz2bFDe4hDG0AK6vRpeRqDPw130_provenance.
- NP113167.RA0r-6_GZilNaoZYtYPT7Qk0uOJQODY9hZ86yfc5PnbN0130_assertion description "[NZ-1 neutralizes the interaction between podoplanin and CLEC-2, which may lead to the development of therapeutic antibodies against podoplanin-dependent cancer metastasis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP113167.RA0r-6_GZilNaoZYtYPT7Qk0uOJQODY9hZ86yfc5PnbN0130_provenance.
- NP166217.RA-xafijZx3Afg84RwTbB5YbDaZ8dXLRiOmbHNh15nkL0130_assertion description "[NZ-1 neutralizes the interaction between podoplanin and CLEC-2, which may lead to the development of therapeutic antibodies against podoplanin-dependent cancer metastasis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP166217.RA-xafijZx3Afg84RwTbB5YbDaZ8dXLRiOmbHNh15nkL0130_provenance.
- NP241087.RA8LTcCTis0YliAeRVe7RoQPS5ikNZLOiy3FRbR-H6YFM130_assertion description "[NZ-1 neutralizes the interaction between podoplanin and CLEC-2, which may lead to the development of therapeutic antibodies against podoplanin-dependent cancer metastasis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP241087.RA8LTcCTis0YliAeRVe7RoQPS5ikNZLOiy3FRbR-H6YFM130_provenance.
- NP176374.RAO3pmDGcF5clo6gFXBIwrZIrI6MLlxcnllDB-T4fNfz8130_assertion description "[NZ-1 neutralizes the interaction between podoplanin and CLEC-2, which may lead to the development of therapeutic antibodies against podoplanin-dependent cancer metastasis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP176374.RAO3pmDGcF5clo6gFXBIwrZIrI6MLlxcnllDB-T4fNfz8130_provenance.
- assertion description "[NZ-1 neutralizes the interaction between podoplanin and CLEC-2, which may lead to the development of therapeutic antibodies against podoplanin-dependent cancer metastasis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP166029.RAgbcCUyl8FKtUeUcFrLISpf3FR5yvhrFcrUqbpBTZ6AI130_assertion description "[NZ-1 neutralizes the interaction between podoplanin and CLEC-2, which may lead to the development of therapeutic antibodies against podoplanin-dependent cancer metastasis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP166029.RAgbcCUyl8FKtUeUcFrLISpf3FR5yvhrFcrUqbpBTZ6AI130_provenance.
- assertion description "[NZ-1 neutralizes the interaction between podoplanin and CLEC-2, which may lead to the development of therapeutic antibodies against podoplanin-dependent cancer metastasis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP175829.RAt3j-5NxbhtMWsmgB2NSo1QqZwyubeFdqE7h5Z7Wpu3g130_assertion description "[NZ-1 neutralizes the interaction between podoplanin and CLEC-2, which may lead to the development of therapeutic antibodies against podoplanin-dependent cancer metastasis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP175829.RAt3j-5NxbhtMWsmgB2NSo1QqZwyubeFdqE7h5Z7Wpu3g130_provenance.
- NP241088.RAFlAx3ylHlvMLqrXx6VuGFUIyh16_uqLDsWctX-HU0es130_assertion description "[NZ-1 neutralizes the interaction between podoplanin and CLEC-2, which may lead to the development of therapeutic antibodies against podoplanin-dependent cancer metastasis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP241088.RAFlAx3ylHlvMLqrXx6VuGFUIyh16_uqLDsWctX-HU0es130_provenance.